Listen to AMCP Unscripted Podcast on Precision Medicine

 

AMCP Unscripted Podcast - Jeff Dunn and Biomarkers, Targeted Therapy, and Managed Care Access

AMCP Unscripted guest, Jeffrey Dunn, PharmD, MBA, President and CEO of Cooperative Benefits Group, about the rapidly evolving treatment landscape for HER2-positive biliary tract cancer (BTC) and its implications for managed care. The discussion covers the importance of biomarker testing and molecular profiling in guiding targeted therapy and other managed care strategies.

Listen Now

Featured Articles

AMCP Partnership Forum: Managing Care in the Wave of Precision Medicine

Precision medicine, the customization of health care to an individual’s genetic profile while accounting for biomarkers and lifestyle, has increasingly been adopted by health care stakeholders to guide the development of treatment options, improve treatment decision making, provide more patient-centered care, and better inform coverage and reimbursement decisions. Despite these benefits, key challenges prevent its broader use and adoption.

Precision Medicine Resources

Speakers for ep 58 of the unscripted podcast smiling

Unscripted - Defining Clinical Utility in Managed Care

In this episode of Unscripted, guest host Steve Kheloussi, Principal Consultant with Kheloussi Consulting, sits down with Dr. John Fox, Senior Medical Director for the Americas at Illumina, to untangle the complexities of clinical utility. Drawing on his experience as a pediatrician and former health plan medical director, Dr. Fox explains why defining clinical utility remains a challenge for the industry and explores its critical role in precision medicine. From ending the "diagnostic odyssey" in pediatric rare diseases to the life-saving impact of large-panel biomarker testing in oncology, they discuss how the true value of a test lies in its power to change patient management and improve net health outcomes.
Medicaid VBPs for Patients Act (MVP Act)

AMCP Research Institute Launches Medication Therapy Management Initiative to Address Mid-Life Dementia Risk, Supported by Grant from Lilly

The AMCP Research Institute announced the launch of a new medication therapy management (MTM) health care improvement initiative designed to assess and manage modifiable risk factors for dementia in asymptomatic, middle-aged adults. The initiative is supported by a generous grant from Lilly and aims to address critical gaps in the identification and intervention of early dementia risk.
Precision Medicine, Quality of Care, Medication Therapy Management (MTM)
AMCP Marketing Insights Program

Researchers from University of Utah Report Findings in Managed Care and Specialty Pharmacy (Optimization of Oncology Biomarker Testing In Managed Care)

Researchers from University of Utah Report Findings in Managed Care and Specialty Pharmacy (Optimization of Oncology Biomarker Testing In Managed Care: Best Practices and Consensus Recommendations From an Amcp Market Insights Program): Drugs and Therapies – Managed Care and Specialty Pharmacy
Precision Medicine, Market Insights
Logo box for the AMCP Unscripted Podcast

Unscripted - HER2-Positive Biliary Tract Cancer: Biomarkers, Targeted Therapy, and Managed Care Access

In this episode of Unscripted, the AMCP podcast, we talk with Jeffrey Dunn, PharmD, MBA, President and CEO of Cooperative Benefits Group, about the rapidly evolving treatment landscape for HER2-positive biliary tract cancer (BTC) and its implications for managed care. The discussion covers the importance of biomarker testing and molecular profiling in guiding targeted therapy, key NCCN guideline considerations across lines of treatment, and the clinical and economic impact of timely access to HER2-directed therapies. We also discuss payer-provider collaboration strategies to improve testing, coverage alignment, and patient access in this rare and aggressive form of cancer.
Logo box for the AMCP Unscripted Podcast

Unscripted - Advancing Personalized Medicine: From Promise to Practice

Personalized medicine has moved from concept to proven science—but implementation lags behind. In this episode of Unscripted, Daryl Pritchard, Senior Vice President of Science Policy at the Personalized Medicine Coalition, discusses how precision medicine is transforming care and where critical gaps remain. He shares findings from recent studies showing how many patients are still lost along the testing-to-treatment pathway, even in well-established areas like non-small cell lung cancer, and explains what’s needed to bridge those gaps. The conversation highlights the role of payers, providers, and policymakers in aligning science, practice, and policy to deliver truly individualized care.